SEARCH

SEARCH BY CITATION

References

  • 1
    Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 2007; 12: 853859.
  • 2
    Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008; 30: 393402.
  • 3
    Zhong H, De Marzo AM, Laughner E et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999; 59: 58305835.
  • 4
    Kondo S, Seo SY, Yoshizaki T et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res. 2006; 66: 98709877.
  • 5
    Yoo YG, Cho S, Park S, Lee MO. The carboxy-terminus of the hepatitis B virus X protein is necessary and sufficient for the activation of hypoxia-inducible factor-1alpha. FEBS Lett. 2004; 577: 121126.
  • 6
    Nakamura M, Bodily JM, Beglin M, Kyo S, Inoue M, Laimins LA. Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology 2009; 387: 442448.
  • 7
    Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol. Cell. Biol. 2004; 24: 52235234.
  • 8
    Kondo S, Wakisaka N, Muramatsu M et al. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J. Virol. 2011; 85: 1125511264.
  • 9
    Helczynska K, Kronblad A, Jögi A et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res. 2003; 63: 14411444.
  • 10
    Darekar S, Georgiou K, Yurchenko M et al. Epstein-Barr virus immortalization of human B-cells leads to stabilization of hypoxia-induced factor 1 alpha, congruent with the Warburg effect. PLoS ONE 2012; 7: e42072.
  • 11
    Wakisaka N, Pagano JS. Epstein-Barr virus induces invasion and metastasis factors. Anticancer Res. 2003; 23: 21332138.
  • 12
    Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993; 122: 518523.
  • 13
    Huang SP, Wu MS, Shun CT et al. Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J. Biomed. Sci. 2005; 12: 229241.
  • 14
    Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003; 63: 23302334.
  • 15
    Liu XH, Kirschenbaum A, Lu M et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. 2002; 277: 5008150086.
  • 16
    Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW. EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Mol. Pharmacol. 2010; 77: 10251036.
  • 17
    Kaidi A, Qualtrough D, Williams AC, Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 2006; 66: 66836691.
  • 18
    Krishnamoorthy S, Jin R, Cai Y et al. 12-Lipoxygenase and the regulation of hypoxia-inducible factor in prostate cancer cells. Exp. Cell Res. 2010; 316: 17061715.
  • 19
    Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res. 2008; 68: 86358642.
  • 20
    Yoshida Y, Nakada M, Harada T et al. The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J. Neurooncol 2010; 98: 4147.
  • 21
    French KJ, Schrecengost RS, Lee BD et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003; 63: 59625969.
  • 22
    Conley SJ, Gheordunescu E, Kakarala P et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl Acad. Sci. U. S. A. 2010; 109: 27842789.
  • 23
    Ravi R, Mookerjee B, Bhujwalla ZM et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000; 14: 3444.
  • 24
    Akakura N, Kobayashi M, Horiuchi I et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001; 61: 65486554.
  • 25
    Aebersold DM, Burri P, Beer KT et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001; 61: 29112916.
  • 26
    Tzao C, Lee SC, Tung HJ et al. Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis. Markers 2008; 25: 141148.
  • 27
    Schrijvers ML, van der Laan BF, de Bock GH et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 161169.
  • 28
    Griffiths EA, Pritchard SA, Valentine HR et al. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br. J. Cancer 2007; 96: 95103.
  • 29
    Takahashi R, Tanaka S, Hiyama T et al. Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol. Rep. 2003; 10: 797802.
  • 30
    Sun HC, Qiu ZJ, Liu J et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int. J. Oncol. 2007; 30: 13591367.
  • 31
    Rajaganeshan R, Prasad R, Guillou PJ et al. The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer. Int. J. Colorectal Dis. 2008; 23: 10491055.
  • 32
    Rasheed S, Harris AL, Tekkis PP et al. Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br. J. Cancer 2009; 100: 16661673.
  • 33
    Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 1998; 17: 30053015.
  • 34
    Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin. 2009; 5: 111137.
  • 35
    Zhang H, Wong CC, Wei H et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012; 31: 17571770.
  • 36
    Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429441.
  • 37
    Fujiwara S, Nakagawa K, Harada H et al. Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas. Int. J. Oncol. 2007; 30: 793802.
  • 38
    Giatromanolaki A, Koukourakis MI, Simopoulos C et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin. Cancer Res. 2004; 10: 79727977.
  • 39
    Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271275.
  • 40
    Koh MY, Spivak-Kroizman T, Venturini S et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1A. Mol. Cancer Ther. 2008; 7: 90100.
  • 41
    Greenberger LM, Horak ID, Filpula D et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 2008; 7: 35983608.
  • 42
    Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 2002; 277: 2993629944.
  • 43
    Kong D, Park EJ, Stephen AG et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 2005; 65: 90479055.
  • 44
    Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc. Natl Acad. Sci. U. S. A. 2009; 106: 23532358.
  • 45
    Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001; 46: 326.
  • 46
    Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat. Rev. Drug Discov. 2006; 5: 993996.
  • 47
    Zhang H, Qian DZ, Tan YS et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl Acad. Sci. U. S. A. 2008; 105: 1957919586.
  • 48
    Toh YM, Li TK. Mitoxantrone inhibits HIF-1α expression in a topoisomerase II-independent pathway. Clin. Cancer Res. 2011; 17: 50265037.
  • 49
    Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl Acad. Sci. U. S. A. 2009; 106: 1791017915.